<DOC>
	<DOCNO>NCT00049023</DOCNO>
	<brief_summary>RATIONALE : Radiolabeled octreotide locate tumor cell deliver radioactive tumor-killing substance without harm normal cell . PURPOSE : This phase I trial study safety effectiveness radiolabeled octreotide treat child advance refractory solid tumor .</brief_summary>
	<brief_title>Radiolabeled Octreotide Treating Children With Advanced Refractory Solid Tumors</brief_title>
	<detailed_description>OBJECTIVES : - Determine maximum tolerate dose yttrium Y 90-DOTA-tyr3-octreotide child advance refractory somatostatin receptor-positive tumor . - Determine short-term long-term safety serious adverse-event profile drug patient . - Determine potential antitumor effect drug patient . - Correlate level somatostatin receptor type 2 expression response patient treated drug . OUTLINE : This dose-escalation study . Patients receive yttrium Y 90-DOTA-tyr3-octreotide IV 5-10 minute day 1 . Treatment repeat every 6 week 3 course absence unacceptable toxicity . Cohorts 3-6 patient receive escalate dos yttrium Y 90-DOTA-tyr3-octreotide maximum tolerate dose ( MTD ) determine . The MTD define dose precede least 2 6 patient experience dose-limiting toxicity . Patients follow weekly treatment course , 6 week last course , every 6 month thereafter life . PROJECTED ACCRUAL : Approximately 25-35 patient accrue study .</detailed_description>
	<mesh_term>Neoplasms</mesh_term>
	<mesh_term>Sarcoma</mesh_term>
	<mesh_term>Neuroblastoma</mesh_term>
	<mesh_term>Carcinoid Tumor</mesh_term>
	<mesh_term>Nervous System Neoplasms</mesh_term>
	<mesh_term>Central Nervous System Neoplasms</mesh_term>
	<mesh_term>Neuroendocrine Tumors</mesh_term>
	<mesh_term>Pheochromocytoma</mesh_term>
	<mesh_term>Malignant Carcinoid Syndrome</mesh_term>
	<mesh_term>Gastrointestinal Neoplasms</mesh_term>
	<mesh_term>Adenoma , Islet Cell</mesh_term>
	<mesh_term>Octreotide</mesh_term>
	<mesh_term>Edotreotide</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically cytologically confirm malignant neoplasm Not amenable standard therapy fail exist first secondline therapy Tumor positive somatostatin receptor OctreoScan within past 4 week At least 1 measurable lesion Lesions previously irradiate must demonstrate progression since radiation At least 1 measurable somatostatin receptorpositive lesion irradiate within past 4 week AND full craniospinal radiation within past 3 month Bone marrow least 40 % cellularity OR least 20 % cellularity one million CD34+ stem cells/kg store No diffuse bone marrow involvement OctreoScan scintigraphy PATIENT CHARACTERISTICS : Age 2 25 Performance status COG 02 OR Karnofsky 60100 % OR Lansky 60100 % Life expectancy 212 month Hematopoietic See Disease Characteristics Absolute neutrophil count least 1,000/mm^3 Platelet count least 100,000/mm^3 Hepatic Bilirubin less 1.5 time normal AST ALT less 2.5 time upper limit normal Renal Creatinine great 1 mg/dL ( child less 5 year age ) Creatinine le 1.2 mg/dL ( child 5 10 year age ) Creatinine le 1.7 mg/dL ( child 10 year age ) AND Glomerular filtration rate least 80 mL/min/m^2 Cardiovascular Shortening fraction least 28 % echocardiogram Ejection fraction least 50 % biplane method echocardiogram No prior congestive heart failure unless ejection fraction least 40 % No unstable angina pectoris No cardiac arrhythmia No symptomatic congestive heart failure Other No concurrent malignancy No significant uncontrolled medical , psychiatric , surgical condition would preclude study compliance No antibodies yttrium Y 90DOTAtyr3octreotide octreotide No prior allergic reaction compound similar chemical biologic composition yttrium Y 90DOTAtyr3octreotide No ongoing active infection Not pregnant nursing Negative pregnancy test Fertile patient must use effective contraception 6 month study participation PRIOR CONCURRENT THERAPY : Biologic therapy Not specify Chemotherapy At least 4 week since prior chemotherapy ( 6 week nitrosoureas mitomycin ) Endocrine therapy More 28 day since prior longacting somatostatin analogues No concurrent somatostatin analogues 12 hour 12 hour study drug administration Concurrent hormonal therapy ( somatostatin analogue ) allow provided patient receive hormonal therapy least 2 month stable disease progressive disease Radiotherapy See Disease Characteristics At least 4 week since prior radiotherapy No prior radiotherapy 25 % bone marrow No prior external beam radiotherapy kidney ( scatter dose less 500 cGy single kidney radiation le 50 % single kidney allow ) Surgery At least 4 week since prior surgery Other Recovered prior therapy At least 4 week since prior investigational drug No concurrent approve investigational antineoplastic therapy except bisphosphonates No concurrent combination antiretroviral therapy HIVpositive patient</criteria>
	<gender>All</gender>
	<minimum_age>2 Years</minimum_age>
	<maximum_age>25 Years</maximum_age>
	<verification_date>June 2016</verification_date>
	<keyword>childhood grade III meningioma</keyword>
	<keyword>disseminate neuroblastoma</keyword>
	<keyword>localize unresectable neuroblastoma</keyword>
	<keyword>metastatic pheochromocytoma</keyword>
	<keyword>metastatic Ewing sarcoma/peripheral primitive neuroectodermal tumor</keyword>
	<keyword>recurrent childhood brain tumor</keyword>
	<keyword>recurrent childhood medulloblastoma</keyword>
	<keyword>recurrent neuroblastoma</keyword>
	<keyword>recurrent pheochromocytoma</keyword>
	<keyword>recurrent Ewing sarcoma/peripheral primitive neuroectodermal tumor</keyword>
	<keyword>regional neuroblastoma</keyword>
	<keyword>regional pheochromocytoma</keyword>
	<keyword>unspecified childhood solid tumor , protocol specific</keyword>
	<keyword>recurrent childhood ependymoma</keyword>
	<keyword>childhood infratentorial ependymoma</keyword>
	<keyword>childhood supratentorial ependymoma</keyword>
	<keyword>recurrent islet cell carcinoma</keyword>
	<keyword>gastrinoma</keyword>
	<keyword>insulinoma</keyword>
	<keyword>metastatic gastrointestinal carcinoid tumor</keyword>
	<keyword>recurrent gastrointestinal carcinoid tumor</keyword>
	<keyword>regional gastrointestinal carcinoid tumor</keyword>
</DOC>